Company & Sponsor Intelligence
New York State Psychiatric Institute
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting0
Completed1
Countries1
Therapeutic footprint
depression
Indexed studies
NCT00136734Methylphenidate Treatment for Cocaine Abuse and ADHD - 1
adhd · United StatesPHASE1
adhd · United StatesPHASE1
NCT05999240Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
autism · United StatesPHASE2
autism · United StatesPHASE2
NCT01658228Combination Treatment Study for Memory Impairment and Depression
depression · United StatesPHASE4
depression · United StatesPHASE4
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →